Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2608-2617

  Aguinagalde, Leire ^a,b,c   Díez Martínez, Roberto ^a,c   Yuste, Jose ^b,c   Royo, Inmaculada ^a   Gil, Carmen ^d   Lasa, Íñigo ^d   Martín Fontecha, Mar ^e   Marín Ramos, Nagore Isabel ^d,e   Ardanuy, Carmen ^c,f   Liñares, Josefina ^c,f   Garcí, Pedro ^a,c   Garcí, Ernesto ^a,c   Sánchez Puelles, José M ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d CSIC   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; AURANOFIN; CEFOXITIN; CHLORAMPHENICOL; CIPROFLOXACIN; ERYTHROMYCIN; GOLD DERIVATIVE; LEVOFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; TETRACYCLINE; TETRAHYDRO 1H PYRROLO[1,2 C]IMIDAZOLE 1,3(2H) DIONE(TRIETHYLPHOSPHINE)GOLD; THIOGLUCOSE; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PNEUMOCOCCAL INFECTION; TREATMENT OUTCOME; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; FEMALE; MICROBIOLOGY; MULTIDRUG RESISTANCE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; AURANOFIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE, INBRED BALB C; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 84954287879     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv163     Document Type: Article

References (40)

1. Bell BG, Schellevis F, Stobberingh E et al. A systematic review and metaanalysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infect Dis 2014; 14: 13.
2. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6: 751-63.
3. Magiorakos A-P, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
4. Padhy BM, Gupta YK. Drug repositioning: re-investigating existing drugs for new therapeutic indications. J Postgrad Med 2011; 57: 153-60.
5. Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod 2014; 77: 703-23.
6. Lacks S, Hotchkiss RD. A study of the genetic material determining an enzyme activity in Pneumococcus. Biochim Biophys Acta 1960; 39: 508-18.
7. Fenoll A, Martín Bourgon C, Muñoz R et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Rev Infect Dis 1991; 13: 56-60.
8. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
9. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-fourth Informational Supplement M100-S24. CLSI, Wayne, PA, USA, 2014.
10. Coates G, Kowala C, Swan J. Coordination compounds of group IB metals. I. Triethylphosphine complexes of gold(I) mercaptides. Aust J Chem 1966; 19: 539-45.
11. Cagnoli M, Alama A, Barbieri F et al. Synthesis and biological activity of gold and tin compounds in ovarian cancer cells. Anti-Cancer Drugs 1998; 9: 603-10.
12. Patent 3784687. Phosphine or Phosphite Gold Complexes of Thioethanol and Derivatives Thereof to Treat Arthritis. 1974. http://www.freepatentsonline.com/3784687.pdf.
13. Price SJB, DiMartino MJ, Hill DT et al. Tertiary phosphine complexes of gold(I) and gold(III) with imido ligands: 1H, 31P, and 15N NMR spectroscopy, antiinflammatory activity, and X-ray crystal structure of (phthalimido)(triethylphosphine)gold(I). Inorg Chem 1985; 24: 3425-34.
14. Yuste J, Botto M, Bottoms SE et al. Serum amyloid P aids complementmediated immunity to Streptococcus pneumoniae. PLoS Pathog 2007; 3: e120.
15. Banevicius MA, Kaplan N, Hafkin B et al. Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model. J Chemother 2013; 25: 26-31.
16. Gil C, Solano C, Burgui S et al. Biofilm matrix exoproteins induce a protective immune response against Staphylococcus aureus biofilm infection. Infect Immun 2014; 82: 1017-29.
17. Ramos-Sevillano E, Rodríguez-Sosa C, Díez-Martínez R et al. Macrolides and β-lactams antibiotics enhance C3b deposition on the surface of multidrug-resistant Streptococcus pneumoniae strains by a LytA autolysindependent mechanism. Antimicrob Agents Chemother 2012; 56: 5534-40.
18. El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. Clin Microbiol Rev 2015; 28: 191-207.
19. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009; 59: S4-S16.
20. Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007; 448: 645-6.
21. Sannella AR, Casini A, Gabbiani C et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett 2008; 582: 844-7.
22. Debnath A, Parsonage D, Andrade RM et al. A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 2012; 18: 950-60.
23. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases. Gut Microbes 2013; 4: 66-71.
24. Tejman-Yarden N, Miyamoto Y, Leitsch D et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 2013; 57: 2029-35.
25. WHO. Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 2007; 82: 93-104.
26. Yanagawa A, Narikawa S, Kudo T et al. Anti-bacterial and anti-fungal effect of several anti-rheumatic drugs. Jpn J Inflammation 1995; 15: 261-4.
27. Cassetta MI, Marzo T, Fallani S et al. Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections. Biometals 2014; 27: 787-91.
28. Hokai Y, Jurkowicz B, Fernández-Gallardo J et al. Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J Inorg Biochem 2014; 138: 81-8.
29. Lu J, Vlamis-Gardikas A, Kandasamy K et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J 2013; 27: 1394-403.
30. Saleh M, Bartual SG, Abdullah MR et al. Molecular architecture of Streptococcus pneumoniae surface thioredoxin-fold lipoproteins crucial for extracellular oxidative stress resistance and maintenance of virulence. EMBO Mol Med 2013; 5: 1852-70.
31. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol 1997; 36: 560-72.
32. Yuste J, Jado I, Fenoll A et al. b-Lactam modification of the bacteraemic profile and its relationship with mortality in a pneumococcal mouse sepsis model. J Antimicrob Chemother 2002; 49: 331-5.
33. Ardanuy C, de la Campa AG, García E et al. Spread of Streptococcus pneumoniae serotype 8-ST63 multidrug-resistant recombinant clone, Spain. Emerg Infect Dis 2014; 20: 1848-56.
34. Huelves L, Sevillano D, Martínez-Marín C et al. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones. Int J Antimicrob Agents 2006; 27: 294-9.
35. Gudiol C, Ayats J, Camoez M et al. Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One 2013; 8: e74734.
36. Vergara-Irigaray M, Valle J, Merino N et al. Relevant role of fibronectinbinding proteins in Staphylococcus aureus biofilm-associated foreign-body infections. Infect Immun 2009; 77: 3978-91.
37. Hoskins J, Alborn WE Jr, Arnold J et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol 2001; 183: 5709-17.
38. Lanie JA, Ng W-L, Kazmierczak KM et al. Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. J Bacteriol 2007; 189: 38-51.
39. Peña C, Gómez-Zorrilla S, Suarez C et al. Extensively drug-resistant Pseudomonas aeruginosa: risk of bloodstream infection in hospitalized patients. Eur J Clin Microb Infect Dis 2012; 31: 2791-7.
40. Peña C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35: 9-16.